Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT06033703 · ClinicalTrials.gov registry record · Phase 1
Topical Netarsudil for the Prevention of Proliferative Vitreoretinopathy in Patients With Retinal Detachment
A Phase 1 study of Rhegmatogenous Retinal Detachment and Proliferative Vitreoretinopathy, sponsored by Massachusetts Eye and Ear Infirmary.
- Recruiting
- Registry status
- Phase 1
- Development phase
- 48
- Enrollment target
- 1
- Study location
NCT06033703: Recruiting Phase 1 study of Rhegmatogenous Retinal Detachment and Proliferative Vitreoretinopathy, sponsored by Massachusetts Eye and Ear Infirmary.
NCT06033703 is a Phase 1 study of Rhegmatogenous Retinal Detachment and Proliferative Vitreoretinopathy that is actively recruiting participants, run by Massachusetts Eye and Ear Infirmary. The registered enrollment target is 48 participants, below the 369-participant average among 3 other Rhegmatogenous Retinal Detachment trials with a reported enrollment target (87% lower). The trial reports 1 study location across 1 state. According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT06033703, a Phase 1 study of Rhegmatogenous Retinal Detachment and Proliferative Vitreoretinopathy, is actively recruiting participants, sponsored by Massachusetts Eye and Ear Infirmary.
- RECRUITING
- Registry status
- Phase 1
- Development phase
- 48 participants
- Enrollment target
- 1
- Study location
Study Summary
This study has two main objectives. The first objective is to study the pharmacokinetics of topical netarsudil administration in the posterior segment of the eye, where netarsudil must exert its effect in order to prevent formation of tractional membranes. The second objective is to assess the safety profile of topical netarsudil in the pre- and post-operative periods. A secondary objective of the study is to begin to assess signs of efficacy in preventing formation of tractional membranes post-operatively.
Primary Outcome
Netarsudil concentration in the posterior segment of the eye, using High-performance liquid chromatography (HPLC)
Conditions Studied
Interventions
- DRUG Netarsudil Ophthalmic
Study Locations (1)
Massachusetts
- Mass Eye and Ear - Boston
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 48 participants |
| Start Date | 2025-01-14 |
| Est. Completion | 2026-12 |
| Phase | Phase 1 |
What NCT06033703 shows while recruiting
NCT06033703 is an interventional study that assigns participants to a tested intervention. The registry caps enrollment at 48 participants, a relatively small participant target, below the 369-participant average among 3 other Rhegmatogenous Retinal Detachment trials with a reported enrollment target (87% lower).
The record links to 2 conditions, with Rhegmatogenous Retinal Detachment appearing as the primary indexed condition, and to 1 intervention - of which Netarsudil Ophthalmic is the first listed.
NCT06033703 reports a single indexed study location in Massachusetts.
Frequently Asked Questions
What is clinical trial NCT06033703 about?
NCT06033703 is a clinical study titled "Topical Netarsudil for the Prevention of Proliferative Vitreoretinopathy in Patients With Retinal Detachment". This study has two main objectives. The first objective is to study the pharmacokinetics of topical netarsudil administration in the posterior segment of the eye, where netarsudil must exert its effect in order to prevent formation of tractional membranes. The second objective is to assess the safe...
What is the current status of trial NCT06033703?
This trial is currently recruiting. It is a Phase 1 study. The enrollment target is 48 participants. The study started on 2025-01-14. Estimated completion is 2026-12.
What conditions does trial NCT06033703 study?
This clinical trial studies the following conditions: Rhegmatogenous Retinal Detachment, Proliferative Vitreoretinopathy.
What interventions are being tested in trial NCT06033703?
The interventions under investigation include: Netarsudil Ophthalmic (DRUG).
Who is sponsoring clinical trial NCT06033703?
This trial is sponsored by Massachusetts Eye and Ear Infirmary, which has 73 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT06033703 being conducted?
This trial has 1 study location across Massachusetts. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Similar trials for Rhegmatogenous Retinal Detachment
Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.
-
Prevention of ProliFerative Vitreoretinopathy with Intravitreal MethotreXate in Primary Retinal DEtachment Repair (FIXER) Trial
RECRUITING · Phase 2
-
Dropless Pars Plana Vitrectomy Study
RECRUITING · Phase 4
-
A Multi-Center Study on the Use of Rho-Kinase Inhibitor to Reduce or Prevent PVR in RRD Eyes at High Risk for PVR
ACTIVE NOT RECRUITING · Phase 2
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar enrollment target
- NCT01765777 · 48 participants · NA
Efficacy of Osteopathic Manipulative Medicine (OMM) and Phototherapy for Patients With Chronic Lower Back Pain
- NCT03073343 · 48 participants · NA
A Prospective, Randomized, Open Label Trial of Two Doses of Oral Betaine
- NCT03431064 · 48 participants
Lung Recruitment Maneuver as a Potential Predictor of Fluid Responsiveness in Mechanically Ventilated Pediatric Patients
- NCT03514602 · 48 participants · NA
Maternal Smoking Cessation and Pediatric Obesity Prevention
Similar registry start date
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia
- NCT07125183 · started 2026-12 · Phase 2
Study on Efficacy and Tolerability of Weekly Doxorubicin in Elderly Patients With Advanced or Metastatic Leiomyosarcoma
- NCT07292298 · started 2026-11 · Phase 2
Phase 2 Single-Arm Rectal Cancer Brachytherapy for Patients With Low-Lying Residual Adenocarcinoma After Total Neoadjuvant Therapy to Improve Organ Preservation Rates
- NCT04263285 · started 2026-10 · NA
Treatment of Depression Post-SCI